Marc Ferrante
Overview
Explore the profile of Marc Ferrante including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
310
Citations
11613
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Greef I, Bislenghi G, Terrasson I, Sabino J, Ferrante M, dHoore A, et al.
Dig Dis
. 2025 Feb;
:1-21.
PMID: 40015256
Introduction Total colectomy for ulcerative colitis (UC) is associated with postoperative morbidity, including venous thromboembolic events (VTE). In light of recent concerns on increased major adverse events associated with JAK...
2.
Panaccione R, Ferrante M, Dotan I, Panes J, Hisamatsu T, Bossuyt P, et al.
Clin Gastroenterol Hepatol
. 2025 Feb;
PMID: 39909280
Background & Aims: The efficacy and safety of extended treatment with risankizumab (RZB), an anti-interleukin-23 p19 monoclonal antibody, were evaluated in patients with moderate to severe Crohn's disease (CD) who...
3.
Bislenghi G, Luberto A, De Coster W, van Langenhoven L, Wolthuis A, Ferrante M, et al.
BJS Open
. 2025 Jan;
9(1).
PMID: 39841130
Background: Proctocolectomy with ileal pouch-anal anastomosis is the treatment of choice for patients with ulcerative colitis with medical refractory disease or dysplasia. The aim of this research was to describe...
4.
Panaccione R, Louis E, Colombel J, DHaens G, Peyrin-Biroulet L, Dubinsky M, et al.
J Crohns Colitis
. 2025 Jan;
19(1).
PMID: 39804294
Background And Aims: Treating ulcerative colitis (UC) in patients with prior advanced therapy (AT) exposure may be challenging. We report the efficacy and safety of risankizumab, a monoclonal interleukin 23p19...
5.
Feagan B, Colombel J, Panaccione R, Schreiber S, Ferrante M, Kamikozuru K, et al.
Gastro Hep Adv
. 2025 Jan;
4(1):100544.
PMID: 39802486
Background And Aims: We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in...
6.
Jorissen T, Fierens L, Bosmans H, Verstockt B, Sabino J, Vermeire S, et al.
J Crohns Colitis
. 2025 Jan;
PMID: 39761345
Background And Aims: Radiological imaging is crucial for diagnosing and monitoring patients with inflammatory bowel diseases (IBD). With increasing awareness of radiation risks, imaging doses should be 'as low as...
7.
Vissers E, Wellens J, Giorio L, Zadora W, Verstockt B, Ferrante M, et al.
Inflamm Bowel Dis
. 2024 Dec;
PMID: 39720875
Background: The consumption of ultra-processed foods has increased significantly worldwide and is associated with the rise in inflammatory bowel diseases. However, any causative factors and their underlying mechanisms are yet...
8.
Outtier A, Janssens R, Barbier L, Sabino J, Verstockt B, Vermeire S, et al.
United European Gastroenterol J
. 2024 Dec;
PMID: 39698868
Background: Eligibility criteria in clinical trials have been criticised for being overly restrictive without clinical justification. Objective: We aimed to investigate the types, evolution, and current status of eligibility criteria...
9.
Hoffert Y, Ferrante M, Verstockt B, Dreesen E
Lancet Gastroenterol Hepatol
. 2024 Dec;
10(1):18-19.
PMID: 39674216
No abstract available.
10.